Day One Biopharmaceuticals (DAWN)

Executive Summary

Day One Biopharmaceuticals is a clinical-stage oncology company that has successfully commercialized its first product, OJEMDA™ (tovorafenib), for pediatric low-grade glioma (pLGG) following FDA approval in 2024. The company's innovative 'Search & Development' model focuses on accelerating targeted therapies for pediatric and adult patients with genetically defined cancers. With OJEMDA now generating revenue, Day One is leveraging its expertise to expand tovorafenib into additional indications and advance its pipeline. The company's pipeline includes a Phase 3 trial (FIREFLY-2) evaluating tovorafenib in combination with chemotherapy for pLGG, a Phase 2 study for recurrent craniopharyngioma, and a Phase 1 trial for DAY301, a next-generation therapy for advanced solid tumors. Key upcoming catalysts include interim data from the craniopharyngioma trial and initial results from DAY301, both expected within the next 12–18 months. While OJEMDA provides a commercial foothold, the company faces risks from competitive pressures and dependence on pipeline success. Overall, Day One is well-positioned in the pediatric oncology space but requires successful pipeline execution to drive long-term growth.

Upcoming Catalysts (preview)

• H2 2026Phase 2 craniopharyngioma trial interim data60% success
• H1 2027DAY301 Phase 1 dose-escalation data50% success
• 2026OJEMDA label expansion for additional pLGG subtypes70% success